Our models complete those published by Sayles (12) with two models harboring amplification of IGF1R (GR-OS-10, focal in GR-OS-12, Figure 5), observed in two out of 129 osteosarcoma patients at diagnosis (http://www.cbioportal.org/study/summary?id=sarcoma_mskcc_2022) and five at relapse (MAPPYACTS), targetable by anti-IGFR antibodies. Here, IGF1R is linked to osteosarcoma.